TGFBR3L: A Potential Drug Target and Biomarker (G100507588)

Target Name: TGFBR3L

NCBI ID: G100507588

TGFBR3L

TGFBR3L: A Potential Drug Target and Biomarker

TGF-β (Transforming Growth Factor-尾) is a cytokine that plays a crucial role in cell growth, differentiation, and regeneration. TGF-β signaling is involved in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The TGF-β receptor (TGFBR) is a transmembrane protein that is composed of two tyrosine residues. TGF-β signaling is activated by the binding of TGF-β dimers to the TGFBR.

TGFBR3L is a TGF-β receptor that is mutated and has been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. TGFBR3L has also been shown to be involved in the development of cancer, including neuroendocrine tumors.

The TGFBR3L gene has been identified as a potential drug target in the treatment of neurodegenerative diseases. By targeting TGFBR3L, researchers hope to develop new treatments for these diseases, which are currently untreatable.

One way to target TGFBR3L is through the use of small molecules, such as those that can inhibit the activity of TGF-β signaling. Small molecules have been shown to be effective in treating neurodegenerative diseases by modulating TGF-β signaling.

Another approach to targeting TGFBR3L is through the use of monoclonal antibodies ( monos), which are laboratory-produced molecules that mimic the function of natural antibodies. Monos can be used to target TGFBR3L and its downstream targets, such as Smad6, in order to inhibit TGF-β signaling.

TGFBR3L has also been shown to be involved in the development of cancer. TGF-β signaling is known to be involved in the regulation of cell proliferation and angiogenesis, which are processes that are critical for the development of cancer. Researchers have shown that TGF-β signaling is activated in many types of cancer, including neuroendocrine tumors.

The TGFBR3L gene has also been implicated in the development of neurodegenerative diseases. TGF-β signaling is known to be involved in the regulation of neuronal excitability and synaptic plasticity, which are processes that are important for the development and maintenance of neural function. Researchers have shown that TGF-β signaling is activated in many neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, TGFBR3L is a protein that is involved in the regulation of TGF-β signaling and has been implicated in the development and progression of many neurodegenerative diseases. The TGFBR3L gene has also been shown to be involved in the development of cancer. Therefore, TGFBR3L is a potential drug target and biomarker for the treatment of neurodegenerative diseases and cancer.

Protein Name: Transforming Growth Factor Beta Receptor 3 Like

The "TGFBR3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TGFBR3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets